Ipilimumab Nivolumab Combination Demonstrated Encouraging Activity in Advanced Melanoma

“The combination of the immunotherapy agents ipilimumab and nivolumab induced extensive and durable tumor shrinkage in patients with advanced melanoma, according to long-term study results presented at the ASCO Annual Meeting.

“ ‘These are two distinct immune checkpoint inhibitors, so it makes sense to combine them together,’ researcher Mario Sznol, MD, a professor of medical oncology at Yale School of Medicine, said during a press conference. ‘They both produce very significant clinical activity as monotherapy in advanced melanoma.’ ”

Editor’s note: Immunotherapy treatments boost a patient’s own immune system to fight cancer. A new immunotherapy treatment combines two individual immunotherapy drugs: ipilimumab (Yervoy) and nivolumab. In a clinical trial to test the combo in volunteer patients with advanced melanoma, the treatment was found to provide promising survival results. Further studies are needed to see just how well the treatment might work.